Bio-Techne (TECH) Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology, USCAP, Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics, ACD, a Bio-Techne brand, will be exhibiting and showcasing RNAscope technology at booth #222.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Coinbase initiated, Block upgraded: Wall Street’s top analyst calls
- Bio-Techne initiated with an Outperform at Evercore ISI
- Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future
- Bio-Techne named short-term buy idea at Deutsche Bank
- Early notable gainers among liquid option names on March 6th